Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02495766 (ClinicalTrials.gov)	May 11, 2015	3/6/2015	Autologous Mesenchymal Stromal Cells for Multiple Sclerosis	Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: XCEL-MC-ALPHA;Drug: Placebo	Banc de Sang i Teixits	Vall d'Hebron Research Institute (VHIR)	Completed	18 Years	60 Years	All	8	Phase 1/Phase 2	Spain
2	NCT01364246 (ClinicalTrials.gov)	January 2010	31/5/2011	Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Progressive Multiple Sclerosis;Neuromyelitis Optica.	Biological: human umbilical cord mesenchymal stem cells	Shenzhen Beike Bio-Technology Co., Ltd.	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;The Affiliated Nanjing Brain Hospital of Nanjing University Medical School;Nanjing University Medical College Affiliated Wuxi Second Hospital;Xuzhou Medical College;The Second Hospital of Nanjing Medical University	Recruiting	18 Years	60 Years	Both	20	Phase 1/Phase 2	China